Celldex Therapeutics , Inc. (NASDAQ:CLDX), a biopharmaceutical company with a market capitalization of $1.6 billion focused on developing innovative therapies for challenging diseases, has been making ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Updating peak systemic mastocytosis franchise revenue opportunity to $4 billion, catalyzed by strong AYVAKIT® (avapritin ...

Morgan Stanley analyst Michael Ulz has maintained their neutral stance on BPMC stock, giving a Hold rating on January 9.Stay Ahead of the ...

Investing.com -- Shares of Blueprint Medicines (NASDAQ: BPMC) Corporation (NASDAQ:BPMC) climbed 17% as the company outlined its growth strategy for 2025, highlighting the potential of its systemic ...

Common types in senior dogs include mast cell tumors, lymphoma, hemangiosarcoma, squamous cell carcinoma, oral melanomas, and ...

Shares of Blueprint Medicines BPMC rallied 18.2% on Monday driven by investor enthusiasm following the company’s announcement ...

Japan’s pet cancer therapeutics sector surges forward, propelled by evolving diagnostic tools, innovative drug breakthroughs, ...

mast cells, etc.) as well as adaptive immune cells (T cells and B cells): CAFs stimulate the polarization of innate immune cells towards pro-tumor subtypes through direct contact, paracrine ...

Mast cells are involved in the immune system’s ... which are also a common symptom of many types of blood cancer. Sweat on the skin’s surface can make it itch more. Several prescription ...